{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:28:56Z","timestamp":1779110936473,"version":"3.51.4"},"reference-count":34,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cProgetto Ricerca Corrente\u201d of the Italian Ministry of Health, Rome, Italy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Adalimumab is the only biologic agent approved for the treatment of moderate-to-severe hidradenitis suppurativa (HS) patients (i.e., with Hurley II or III), which is recommended in two different maintenance doses (i.e., 40 mg weekly or 80 mg every two weeks). We conducted a prospective multicentric study to measure outcomes related to the severity of disease and quality of life (QoL) of patients affected by moderate-to-severe HS, treated with adalimumab at a maintenance dosing of 40 mg or 80 mg. Assessments were performed at baseline (T0) and after 32 weeks of treatment (T32). We enrolled 85 moderate-to-severe HS Italian patients, 43 men (50.6%) and 42 women, aged between 16 and 62 years (median 31 years, interquartile range 24.4\u201343.8). Statistically significant improvements were observed for clinical status (with a mean reduction of 7.1 points for the International Hidradenitis Suppurativa Severity Score System (IHS4)), pain levels (3.1 mean decrease in VAS), and QoL (3.4 mean improvement in DLQI score). Patients with no comorbidities, and those with higher levels of perceived pain showed significantly greater improvement in QoL than their counterpart from T0 to T32. As for the proportion of patients who at follow-up reached the minimal clinical important difference (MCID) in QoL, significantly higher proportions of success were observed for age (patients in the 29\u201339 category), pain (patients with higher reported pain), and Hurley stage III. While both treatment regimen groups (i.e., 40 vs. 80 mg) improved significantly, no statistical differences were observed when comparing the two treatment dosages.<\/jats:p>","DOI":"10.3390\/jcm11144037","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T20:52:41Z","timestamp":1657659161000},"page":"4037","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa"],"prefix":"10.3390","volume":"11","author":[{"given":"Luca","family":"Fania","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell\u2019Immacolata, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Giovanardi","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell\u2019Immacolata, IDI-IRCCS, 00167 Rome, Italy"},{"name":"Department of Dermatology, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5588-5999","authenticated-orcid":false,"given":"Tonia","family":"Samela","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell\u2019Immacolata, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dante","family":"Caposiena","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flaminia","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Saraceni","sequence":"additional","affiliation":[{"name":"Istituto Dermatologico San Gallicano, IRCCS, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvia","family":"Elia","sequence":"additional","affiliation":[{"name":"Istituto Dermatologico San Gallicano, IRCCS, 00144 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Garcovich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Ciccone","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell\u2019Immacolata, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Vittoria","family":"Cannizzaro","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Miraglia","sequence":"additional","affiliation":[{"name":"Dermatology Clinic Umberto I, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Iacovino","sequence":"additional","affiliation":[{"name":"Dermatology Clinic Umberto I, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Giustini","sequence":"additional","affiliation":[{"name":"Dermatology Clinic Umberto I, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4478-5404","authenticated-orcid":false,"given":"Nevena","family":"Skroza","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Surgical Sciences and Biotechnologies, Daniele Innocenzi, Sapienza University of Rome\u2014Polo Pontino, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Mambrin","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Surgical Sciences and Biotechnologies, Daniele Innocenzi, Sapienza University of Rome\u2014Polo Pontino, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical and Surgical Sciences and Biotechnologies, Daniele Innocenzi, Sapienza University of Rome\u2014Polo Pontino, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-6896","authenticated-orcid":false,"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-6600","authenticated-orcid":false,"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0167-7617","authenticated-orcid":false,"given":"Damiano","family":"Abeni","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit and Dermatology Department, Istituto Dermopatico dell\u2019Immacolata, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1159\/000509873","article-title":"Phenotypes and Pathophysiology of Syndromic Hidradenitis Suppurativa: Different Faces of the Same Disease? A Systematic Review","volume":"237","author":"Nikolakis","year":"2021","journal-title":"Dermatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis Suppurativa: Advances in Diagnosis and Treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaad.2013.06.042","article-title":"Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States","volume":"69","author":"Cosmatos","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1111\/jdv.14224","article-title":"Prevalence and incidence of hidradenitis suppurativa: An exercise on indirect estimation from psoriasis data","volume":"31","author":"Fania","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bjd.16101","article-title":"Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa","volume":"178","author":"Ingram","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaad.2017.02.005","article-title":"Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis","volume":"77","author":"Garg","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3389\/fimmu.2019.01059","article-title":"Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases","volume":"10","author":"Marzano","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000517017","article-title":"Metabolic Disorders\/Obesity Is a Primary Risk Factor in Hidradenitis Suppurativa: An Immunohistochemical Real-World Approach","volume":"238","author":"Kaleta","year":"2022","journal-title":"Dermatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coph.2019.04.006","article-title":"Pharmacological development in hidradenitis suppurativa","volume":"46","author":"Matusiak","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","unstructured":"EMA (2015). First Medicine Recommended for Approval for Hidradenitis Suppurativa, EMA."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CCID.S111019","article-title":"Hidradenitis suppurativa: From pathogenesis to diagnosis and treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000503606","article-title":"Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa\/Acne Inversa","volume":"236","author":"Zouboulis","year":"2020","journal-title":"Dermatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1111\/jdv.17178","article-title":"Effectiveness of Secukinumab in the treatment of moderate\u2013severe hidradenitis suppurativa: Results from an Italian multicentric retrospective study in a real-life setting","volume":"35","author":"Ribero","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"316.e2","DOI":"10.1016\/j.jid.2020.06.019","article-title":"A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance","volume":"141","author":"Frew","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.det.2015.08.009","article-title":"Diagnosing Hidradenitis Suppurativa","volume":"34","author":"Revuz","year":"2016","journal-title":"Dermatol. Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","article-title":"New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes","volume":"73","author":"Jemec","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): A novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): Further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0304-3959(83)90126-4","article-title":"The validation of visual analogue scales as ratio scale measures for chronic and experimental pain","volume":"17","author":"Price","year":"1983","journal-title":"Pain"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014A simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Krajewski, P.K., Matusiak, \u0141., von Stebut, E., Schultheis, M., Kirschner, U., Nikolakis, G., and Szepietowski, J.C. (2021). Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients. Life, 11.","DOI":"10.3390\/life11010034"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.17551","article-title":"Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study","volume":"35","author":"Hafner","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: A retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1001\/archinte.163.20.2433","article-title":"Depression and pain comorbidity: A literature review","volume":"163","author":"Bair","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamadermatol.2019.0759","article-title":"Depression and Anxiety in Adults with Hidradenitis Suppurativa","volume":"155","author":"Machado","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","article-title":"Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa [corrected]","volume":"21","author":"Patel","year":"2017","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00403-020-02063-4","article-title":"Age-specific physical and mental health status in Italian patients with hidradenitis suppurativa: A comparison with the general population","volume":"313","author":"Sampogna","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/postgradmedj-2013-131994","article-title":"Hidradenitis suppurativa: A common and burdensome, yet under-recognised, inflammatory skin disease","volume":"90","author":"Dufour","year":"2014","journal-title":"Postgrad. Med. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jdv.12567","article-title":"Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa","volume":"29","author":"Shavit","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1111\/jdv.16290","article-title":"The impact of hidradenitis suppurativa on general health is higher than that of hypertension, congestive heart failure, type 2 diabetes, myocardial infarction and depression","volume":"34","author":"Sampogna","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/14\/4037\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:49:04Z","timestamp":1760140144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/14\/4037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":34,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jcm11144037"],"URL":"https:\/\/doi.org\/10.3390\/jcm11144037","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]}}}